# OnCo record charles-sawyers (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/charles-sawyers/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "charles-sawyers" ;
  schema:name "Charles L. Sawyers"@en ;
  schema:description "Co-developed imatinib's successor dasatinib and the prostate drug enzalutamide, and explained how cancers resist targeted drugs."@en ;
  schema:url <https://onco.cc/people/charles-sawyers/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Charles_Sawyers>, <https://orcid.org/0000-0003-4955-6475> ;
  schema:citation <https://www.mskcc.org/research-areas/labs/charles-sawyers>, <https://pubmed.ncbi.nlm.nih.gov/?term=Sawyers%20CL%5BAuthor%5D> ;
  schema:jobTitle "Chair, Human Oncology and Pathogenesis Program; HHMI Investigator" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/bcr-abl/> ;
  onco:drugs <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/apalutamide/>, <https://onco.cc/drugs/dasatinib/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/> ;
  schema:affiliation <https://onco.cc/institutions/mskcc/> .